Lisen Arnheim Dahlström

Lisen Arnheim Dahlström

Affiliated to Research | Docent
Visiting address: Nobels väg 12a, 17165 Stockholm
Postal address: C8 Medicinsk epidemiologi och biostatistik, C8 MEB III, 171 77 Stockholm

About me

  • * Bachelor of Science (Hons) in Biomedical Sciences, Manchester Metropolitan
    University, England. Major in Medical Microbiology.
    * Doctor of Philosophy (PhD in Infectious Disease Control (Smittskydd),
    Department of Microbiology, Tumor and Cell biology, Karolinska Institutet.
    Title of Thesis: Immunological responses in genital HPV infection and
    etiology of cervical cancer


  • My research is within infectious disease epidemiology and has a main focus on
    prerequisites for optimal vaccination strategies. As vaccination is one of
    our most important tools in the combat of infectious disease it is important
    to maintain public trust. One way of doing this is to evaluate vaccine
    effectiveness and safety on a population-based level. We have in the past
    decades reduced the infectious disease burden with vaccination and we are now
    facing a situation where younger generations who never confronted the actual
    disease tend to shift their focus toward adverse events instead leading to
    anti-vaccine movements and misunderstandings about real and perceived risks.
    Further, with antibiotic resistance we need to develop new vaccines that need
    to be evaluated on a population-based level.
    In addition to this I am also involved in several projects optimizing
    cervical cancer prevention through both vaccination and screening. In our
    group we use sophisticated population-based register matching and modelling
    methods in combination with lab and questionnaire data to evaluate:
    1) Short and long term vaccine safety and effectiveness to ensure the
    reliability of the vaccines

  • 2) Infectious disease burden to investigate both effectiveness and
    cost-effectiveness of vaccine programmes

  • 3) Cervical screening setting and recommendations in a changing reality, as
    the HPV vaccine and new screening techniques will change the program we have
    *Ongoing research projects*
    * ACCES Advancing Cervical Cancer Eradication Strategies [1]
    *Selected publications*
    Association of varying number of doses of quadrivalent human papillomavirus
    vaccine with incidence of condyloma. [2]
    Herweijer E, Leval A, Ploner A, Eloranta S, Simard JF, Dillner J, /et al/
    /JAMA 2014 Feb
  • 311(6):597-603/
    A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed
    in conjunction with the Pandemrix vaccination campaign in Sweden 2009-2010.
    Lind A, Ramelius A, Olsson T, Arnheim-Dahlström L, Lamb F, Khademi M, /et
    /J. Autoimmun. 2014 May
  • 50():99-106/
    Autoimmune, neurological, and venous thromboembolic adverse events after
    immunisation of adolescent girls with quadrivalent human papillomavirus
    vaccine in Denmark and Sweden: cohort study. [4]
    Arnheim-Dahlström L, Pasternak B, Svanström H, Sparén P, Hviid A
    /BMJ 2013 Oct
  • 347():f5906/
    Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national
    cohort study. [5]
    Leval A, Herweijer E, Ploner A, Eloranta S, Fridman Simard J, Dillner J, /et
    /J. Natl. Cancer Inst. 2013 Apr
  • 105(7):469-74/
    Risk of presentation to hospital with epileptic seizures after vaccination
    with monovalent AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine
    (Pandemrix): self controlled case series study. [6]
    Arnheim-Dahlström L, Hällgren J, Weibull CE, Sparén P
    /BMJ 2012 Dec
  • 345():e7594/
    [2] 24519299
    [3] 24485154
    [4] 24108159
    [5] 23486550
    [6] 23274350


All other publications


  • Affiliated to Research, Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 2022-2024

Degrees and Education

  • Docent, Karolinska Institutet, 2013
  • Doctor Of Philosophy, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2005

News from KI

Events from KI